ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Safely Reduce a Common Cause of Stomach Distress

 
Print Page
Email Article

Dramatic Advancement in Treating Juvenile Rheumatoid Arthritis

  [ 1 vote ]   [ Discuss This Article ]
By News Release • www.ProHealth.com • January 10, 2000


A study conducted by researchers at Children's Hospital Medical Center of Cincinnati shows that nearly 75 percent of children with severe, longstanding juvenile rheumatoid arthritis (JRA) respond, often dramatically, to Enbrel (etanercept), a new drug.

The study is published in this week's edition of The New England Journal of Medicine.
"Enbrel represents the most dramatic advancement in treating JRA in recent years and is an improvement over current therapies in terms of both safety and effectiveness," says Daniel J. Lovell, M.D., M.P.H., a pediatric rheumatologist at Cincinnati Children's and principal investigator of the national study.

"Some patients who had been wheelchair-bound and so stricken by side effects from their old treatment that they couldn't go to school are walking around, going to school and involved in
extracurricular activities within a matter of weeks of taking Enbrel."

The study was conducted in two segments. In the first segment, which evaluated Enbrel's safety, 74 percent of children (51 of 69) between the ages of 4 and 17 showed an improvement in disease response when treated with Enbrel for three months.

In the second segment, half of these 51 patients received Enbrel and half received a placebo. Seventy-two percent of those who received Enbrel completed the second segment without worsening of JRA symptoms, compared to 19 percent who took a placebo.

For those whose symptoms did worsen, it took 116 days on average for those who continued on Enbrel, while it took only 28 days on average for those on a placebo. Overall, 80 percent of the Enbrel group experienced at least a 30 percent improvement in disease activity and impact, and more than 40 percent experienced at least a 70 percent improvement in disease activity.

The study, coordinated at Cincinnati Children's, shows that Enbrel eases joint pain and swelling and enhances mobility for JRA patients. "Children and teenagers who struggle with this disease, and their families, face the possibility of a lifetime of pain and, often, disability," says Dr. Edward Giannini, professor of pediatrics in Cincinnati Children's division of rheumatology.
"Enbrel proves that the principle of attacking a specific aspect of the immune response is an effective way to intervene in the disease process."

Enbrel is a protein-based drug that inhibits the binding of tumor necrosis factor (TNF), a protein secreted by different types of cells that regulates the immune response. Normally, when a person gets a viral or bacterial infection, these proteins help fight off the infection. JRA, however, is an autoimmune disease in which these proteins create a cascade of inflammatory effects in joints that can actually destroy one's own joint tissue. Enbrel acts as a sponge to absorb TNF so that it does not bind to receptors on the surface of certain cells, thereby blocking TNF and suppressing the cascade reaction.

The study was conducted in collaboration with Immunex Corporation and the Pediatric Rheumatology Collaborative Study Group (PRCSG), headquartered at Cincinnati Children's and chaired by Dr. Lovell. Dr. Giannini is senior scientist of the PRCSG. The U.S. Food and Drug Administration (FDA) participated in the design and execution of the study.

Based in part on this study, the FDA approved Enbrel for the treatment of polyarticular course JRA (a common form of the disease) in May 1999 and to treat severe to moderate rheumatoid arthritis in November 1999.

Many children in the study have continued on treatment. Studies of these children have concluded that Enbrel is safe and well tolerated even with prolonged use.

Source: Immunex



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Energy NADH™ 12.5mg Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Prepare Yourself for Cold & Flu Season Prepare Yourself for Cold & Flu Season
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera Soothe, Heal and Regulate Your Digestive System with Nutrient-Rich Aloe Vera

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map